Julien Torgue, Ph.D.
His career started as a Project Manager at a Contract Manufacturing Organization, Goodwin Biotechnology, where he oversaw the development, production and regulatory filings of antibodies for clinical trials. In 2010, he transitioned to a Senior Scientist and Project Manager at another CMO, Paragon, prior to accepting the position of Scientific Director for the recently formed biotech, Orano Med (previously AREVA Med). He was tasked with filing an IND for the first in human use of ²¹²Pb, which was submitted to the FDA in December 2010, managing the Phase 1 clinical trial and multiple other scientific partnerships with academic and industrial partners. As Orano Med expanded, he took an increasing role in the strategic development of the company and continues to oversee Orano Med research programs and external collaborations as CSO. Dr. Torgue was elected member of the Macrocyclics board of directors in July 2015 and to the board of Orano Med in January 2017.